AMPH (Amphastar Pharmaceuticals) ROCE %: 4.50% (As of Mar. 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $21.02
GF Value $48.78
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals ROCE %?

Amphastar Pharmaceuticals AMPH +7.74% 83 ROCE % is 4.50% as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Amphastar Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 4.50%.

Amphastar Pharmaceuticals  (NAS:AMPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Amphastar Pharmaceuticals ROCE % Related Terms

Amphastar Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals ROCE % Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.65 19.41 20.52 16.36 10.37

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.50 12.73 7.67 10.52 4.50
AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals ROCE % Calculation

Amphastar Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=149.105/( ( (1577.47 - 173.759) + (1629.299 - 158.156) )/ 2 )
=149.105/( (1403.711+1471.143)/ 2 )
=149.105/1437.427
=10.37 %

Amphastar Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=66.42/( ( (1629.299 - 158.156) + (1648.162 - 164.478) )/ 2 )
=66.42/( ( 1471.143 + 1483.684 )/ 2 )
=66.42/1477.4135
=4.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.50% mean?
Amphastar Pharmaceuticals (AMPH) has a ROCE % of 4.50% as of Mar. 2026.
Is Amphastar Pharmaceuticals' ROCE % too high?
Amphastar Pharmaceuticals' current ROCE % is 4.50%. The Drug Manufacturers industry median ROCE % is 7.00. Amphastar Pharmaceuticals' value of 4.50% is 35.7% below this industry median. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' ROCE % compare to ETON and ESPR?
Amphastar Pharmaceuticals' ROCE % of 4.50% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Amphastar Pharmaceuticals' value of 4.50% is 35.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amphastar Pharmaceuticals's current ROCE % of 4.50% is 35.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amphastar Pharmaceuticals's current ROCE % is 4.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $21.02 — trading 56.9% below its estimated fair value. The current ROCE % is 4.50% and 35.7% below the Drug Manufacturers industry median of 7.00. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current ROCE % is 4.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $21.02 is trading 56.9% below its estimated GF Value™ of $48.78. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • ROCE %: 4.50%
  • GF Value™: $48.78 vs. price of $21.02 (56.9% below fair value)
  • GF Score™: 83/100 with 5 warning signs
  • Industry Position: 35.7% below the Drug Manufacturers median

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.02
Price
$48.78
GF Value